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Public discussion of pharmaceutical policy has finally
begun in Finland. The Ministry of Social Affairs and
Health arranged a hearing on the subject on 14 March
2003. Nearly 20 years had passed since the previous
discussion, which arose during the drafting of the Medi-
cines Act. An even longer period – more than 30 years –
has lapsed since pharmaceutical matters were discussed
at committee level by the Pajula Committees I and II. It
is high time that political decision-makers review the
tenability of the medicine policy in a changed Finland
and world.
Most of the time, the first pharmaceutical policy is-
sue raised by the media is pharmacy-related. This is un-
derstandable, as the consumer and patient encounter
medicines primarily and repeatedly at the pharmacy.
Easy availability and safety of medicines are felt to be
essential, basic points of departure. In a broader view,
and especially when assessing health policy, other ques-
tions rise in priority. For this reason, pharmaceutical
policy is a necessary means for placing issues into an or-
der of importance.
In my opinion, it is clear that the greatest challenge
to pharmaceutical policy in the coming years will con-
cern the funding of pharmacotherapy, and the related
pertinent issue of sensible prescribing and use of medi-
cines. When resources are limited, their rational use is
emphasised. It is a question of priorities, as discussed
widely in health care in general. What pharmaceutical
and medical therapies are used, who is treated, how is
the treatment funded, what is a fair and socially accept-
able level of excess, and how can the impartial availabil-
ity of medicines be assured? These are the questions that
our pharmaceutical policy should address.
In a proposal drawn up by officials of the Ministry
of Social Affairs and Health, the possibility of changing
to a reimbursement based on cost and insurance policies
was presented. This would increase the transparency of
the medicines reimbursement system. The level of reim-
bursements in Finland should correspond to the prac-
tices of those EU member states comparable to our
country. 
Finland can act independently to maintain medicines
safety and ensure the availability of medicines, but
much is reliant on the European operating environment.
Safety of medicines can be maintained, if the authorities
and health care professionals understand it to be a top
priority for medicines control, research, manufacture,
prescribing, distribution and usage. Neglecting any one
of these components will endanger the whole system.
The significance of the pharmaceutical industry with-
in the so-called health cluster should be taken into con-
sideration under pharmaceutical policy. The effects of
the pharmaceutical industry, as reflected on basic and
clinical research, and on changes in treatment regimes,
are aspects of a comprehensive health and pharmaceuti-
cal policy.
A sparsely populated country poses extra challenges
to the supply of health services of a high professional
standard and their easy accessibility. In Finnish pharma-
ceutical services, this matter has been competitively
dealt with compared to other countries. Any medicine
has always been found on pharmacy shelves, and in re-
cent years this has been supplemented with an informa-
tion service. This extensive service does, however, come
with a price, and in Finland this price has been translat-
ed to the pharmacy fee. For pharmaceutical policy pur-
poses, it should be contemplated whether a well-run,
professional basic service could be achieved without the
price-raising effect of the pharmacy fee.
When reforming pharmaceutical policy, one should
dare to challenge former truths. Similarly, one should
have the courage to admit if some matters, even after
consideration, still stand on firm ground. Changes for
the sake of change are not desirable. The known prob-
lems of health care services in Finland result in caution
in the assessment of new directions in pharmaceutical
policy.
Hannes Wahlroos
DIRECTOR GENERAL
National Agency for Medicines
Public discussion of pharmaceutical policy starts up
Editorial
Summary 
Translation Liisa Fellman-Paul
In 2002, the ADR Register of the
National Agency for Medicines re-
ceived a total of 805 reports on sus-
pected adverse drug reactions
(ADRs), about half of which were
serious. There were ten or more re-
ports on 19 different medicinal sub-
stances (Table). The substances at
the top of the list were by and large
the same as in the previous year.
Many of the drugs were recently
launched.  Generally, a greater num-
ber of reports of new drugs is re-
ceived than of old familiar drugs.
The attached list cannot be used for
the comparative evaluation of the
safety of the drugs as there is a con-
siderable variation in the number of
users: a drug used frequently may be
associated with a greater number of
reports than a less frequently used
one despite equal incidence of the
adverse reaction.
The majority of ADR reports in
2002 concerned an anti-inflammato-
ry analgesic nimesulide (48 reports).
Liver reactions were the cause of
nearly all the reports. Due to  seri-
ous liver reactions, nimesulide
tablets and dose granules were sus-
pended from the Finnish drug mar-
ket in March 2002. Due to the safe-
ty concerns, a referral on nime-
sulide, in accordance with EU Direc-
tive, was initiated by the Committee
for Proprietary Medicinal Products
(CPMP).This review leads eventually
to a Commission decision which will
be common to all EU countries.
Marketing authorisation for nime-
sulide is approved in ten EU coun-
tries (Belgium, Spain, Ireland, Italy,
Austria, Greece, Luxembourg, Por-
tugal, France and Finland). In addi-
tion to Finland,  the marketing of
nimesulide is suspended in Spain due
to its adverse liver reactions.
A total of 45 suspected adverse
reactions were reported during the
use of COX 2-selective anti-inflam-
matory analgesics, rofecoxib and
celecoxib (26 on rofecoxib and 19
on celecoxib). A large proportion of
the reports on rofecoxib (10) were
of oedema, weight gain and/or ele-
vated serum creatinine concentra-
tion. Hepatitis was reported in two
patients receiving rofecoxib; nime-
sulide was also suspected in one of
these patients and esomeprazole in
the other. The majority of adverse
reactions associated with celecoxib
therapy were various allergic symp-
toms and rashes (11 cases). Oedema,
weight gain or elevated creatinine
concentration was reported in three
patients on celecoxib therapy. Cau-
tion should be exercised in the use
of coxibs, for instance, in patients
with cardiac insufficiency or hyper-
42 TABU 2.2003
Adverse drug reactions reported to the Finnish
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Medicinal  substances most  f requently  reported to the ADR Register  
of  the National  Agency for  Medicines in 2002
number 
medicinal substance of reports
nimesulide (Nimed) 48
clozapin (Leponex, Froidir) 44
rofecoxib  (Vioxx, Vioxxakut) 26
iopromide (Ultravist) 23
atorvastatin (Lipitor) 20
terbinafine (Lamisil) 19
levofloxacin (Tavanic) 19
celecoxib (Celebra) 19
esomeprazole (Nexium) 18
sulfasalazine (Salazopyrin, Salazopyrin EN) 16
risperidone (Risperdal) 16
infliximab (Remicade) 15
simvastatin (several preparations incl. Corolin, Lipcut, Zocor) 14
oxcarbazepine (Apydan, Trileptal) 14
leflunomide (Arava) 13
quetiapine (Seroquel) 13
nitrofurantoin (Nitrofur-C) 10
paclitaxel (Taxol) 10
carbamazepine (several preparations incl. Tegretol, Neurotol) 10
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tension because the inhibition of re-
nal prostaglandin synthesis may re-
duce renal function and cause accu-
mulation of fluid.
As in previous years, the most
frequently reported antirheumatics
were infliximab (15) and lefluno-
mide (13). Infliximab is a monoclon-
al antibody which inhibits the bio-
logical activity of  tumour necrosis
factor alfa (TNF-α). In addition to
severe, active rheumatoid arthritis, it
is also used in the treatment of
Crohn’s disease, for example, when
the  response to other therapies has
been inadequate. Last year, a serious
infection was reported in six pa-
tients who had received infliximab;
two of the patients had pulmonary
tuberculosis. Infliximab was suspect-
ed to be associated with the devel-
opment of malignancy in two pa-
tients (ovarian cancer, lymphoma).
Infliximab is known to increase sus-
ceptibility to infections due to its
immunosuppressive effect and is
consequently contraindicated in pa-
tients with tuberculosis or other se-
vere infection. Patients should also
be carefully monitored prior to the
treatment, during the treatment and
for six months after the treatment to
exclude tuberculosis and other infec-
tions. At present it is unknown if ex-
posure to infliximab can increase the
incidence of malignant diseases.
Three cases of granulocytopaenia
and two cases of elevated liver en-
zymes were reported in association
with the use of leflunomide. Leflun-
omide may also cause serious liver
reactions and consequently the 
S-ALAT level should be determined
prior to leflunomide therapy. 
S-ALAT level should also be regu-
larly monitored during treatment.
Adverse effects on the blood count
also require regular monitoring by
laboratory tests (see Summary of
Product Characteristics). Concomi-
tant therapy with other hepatotoxic
or haematotoxic medicinal sub-
stances (e.g. methotrexate) is not
recommended as the risk of these se-
rious reactions may be increased.
Among old antirheumatics, the
largest number of reports received
was on sulfasalazine (16). The ad-
verse reaction reported in the major-
ity of the cases was granulocytopae-
nia or agranulocytosis. Two patients
were reported as having elevated 
liver enzymes, and one had hepatitis.
To avoid these well known adverse
reactions, the blood count (leuco-
cytes and differential count) and 
liver function should be determined
at the beginning of treatment and
every second week during the first
three months of treatment. During
the following three months the
analyses are carried out at four
weeks’ intervals, and the blood
count and liver function are there-
after determined at three months’ in-
tervals. In addition to the treatment
of rheumatoid arthritis, sulfasalazine
is also used in the medical treatment
of inflammatory intestinal diseases.
Among drugs used in psychiatric
disorders, the majority of reports
were received on the second genera-
tion antipsychotics, clozapine (44),
risperidone (16) and quetiapine (13).
The majority of reports concern-
ing clozapine were cases of granulo-
cytopaenia or agranulocytosis. The
blood count is altered in one percent
of patients on clozapine therapy,
and the leucocyte count should
therefore be carried out prior to
treatment and regularly during med-
ication. One of the patients on
clozapine therapy was reported as
having cardiomyopathy. The patient
was concomitantly receiving olanza-
pine, which was also suspected drug
in this reaction. The patient recov-
ered when these drugs were with-
drawn and the patient received med-
ical treatment for cardiac insuffi-
ciency. Due to the risks associated
with the use of clozapine, its Sum-
mary of Product Characteristics has
recently been updated and harmon-
ised in the EU. Its previous thera-
peutic indications included patients
with schizophrenia who do not re-
spond to conventional neuroleptic
agents or do not tolerate them. A
mention of the new generation an-
tipsychotics has now been included
in the therapeutic indications. A spe-
cial warning of agranulocytosis and
myocarditis has been framed in and
placed at the beginning of the prod-
uct information. Paralytic ileus and
the concurrent use of drugs known
to have a high risk of causing agran-
ulocytosis, for example, have been
included among the contraindica-
tions.
Granulocytopaenia associated
with the use of quetiapine was re-
ported in four patients. Other ad-
verse reactions included neuroleptic
malignant syndrome in three pa-
tients on quetiapine therapy. The
syndrome is characterised by fever,
severe muscular stiffness, elevated
concentration of creatinine phospho-
kinase and myoglobinuria caused by
muscular damage, electrolyte imbal-
ance, hepatic and renal dysfunction
and reduced level of consciousness.
If symptoms of neuroleptic malig-
nant syndrome appear, the medica-
tion causing the syndrome should be
interrupted and the patient treated
with, for example, bromocriptine or
dantrolene. Medication with an-
tipsychotics can be re-introduced af-
ter 2–4 weeks using an antipsychotic
of some group other than that of the
drug causing the symptoms.
The majority of the adverse reac-
tions caused by risperidone were
hormonal reactions (hyperprolacti-
naemia, menstrual irregularities and
secretion of milk). Risperidone
blocks dopamine receptors and may
by this mechanism increase prolactin
concentration. The old conventional
antipsychotics also have a similar
characteristic, but it is less signifi-
cant with the newer, second genera-
tion antipsychotics. If the adverse re-
actions which have developed as a
result of the elevated concentration
of prolactin are significant, it may
be beneficial to decrease the dose or
replace the antipsychotic with an-
other substance which has only a
minor effect on the serum prolactin
or lacks the effect. Extrapyramidal
symptoms were reported in two pa-
tients and neuroleptic malignant
syndrome in one patient receiving
risperidone.
The majority of reports received
on cholesterol-synthesis-inhibiting
statins last year were about the use
of atorvastatin (20 reports) and sim-
vastatin (14 reports). The most typi-
cal adverse reaction associated with
the use of atorvastatin was muscular
pains and/or increased concentration
of creatinine phosphokinase (11 re-
ports). Elevated liver enzyme levels
were reported in five patients. Mus-
cular symptoms associated with the
use of simvastatin were reported in
seven patients, with the diagnosis of
rhabdomyolysis in one patient. The
patient was given concurrent 
clarithromycin which inhibits the cy-
tochrome P450 3A4 enzyme and in-
creases the risk of muscular injuries
when used concurrently with statins
which are metabolised by the en-
zyme (atorvastatin, lovastatin, sim-
vastatin).
The majority of reports of ad-
verse reactions caused by antibacte-
rials were on levofloxacin (19 re-
ports) of the fluoroquinolone group.
Most of these reports (16) related to
adverse effects on the Achilles ten-
don (tendinitis and rupture of ten-
don). Nearly all the patients were
over 70 years of age and a large
number of them were concurrently
receiving a systemic corticosteroid
which increases the risk of rupture
of the tendon. If tendinitis is sus-
pected, the use of fluoroquinolones
should be terminated immediately.
A total of ten reports were re-
ceived last year of the adverse reac-
tion to nitrofurantoin which is used
in the treatment of urinary tract in-
fections. The reason for the report-
ing in six cases was serious pul-
monary reaction (pulmonary infil-
trate or fibrosis), two patients were
also reported as having dyspnoea.
Nitrofurantoin was used as long-
term therapy in four of the patients,
whereas the rest of the patients were
treated for acute infection. Due to
the risk of serious pulmonary reac-
tions, all respiratory symptoms such
as cough and dyspnoea in patients
on nitrofurantoin should receive
special attention.
Among antifungals, the majority
of the reports of adverse effects were
associated with the use of terbin-
afine tablets (19 reports). The most
common reactions included various
skin reactions (9). Liver reactions
were also reported (two elevated 
liver enzymes and one cholestatic
hepatitis).
The majority of reports concern-
ing antiepileptics were on the use of
oxcarbazepine (14) and carbamaz-
epine (10). Two of the cases of ox-
carbazepine involved oedema and
two hyponatraemia. The rest of the
reports were on single adverse reac-
tions. During carbamezepine thera-
py, various skin reactions (5) and 
elevated liver enzymes (2)  were re-
ported.
The majority of reports of ad-
verse reactions caused by drugs for
gastrointestinal disorders were asso-
ciated with the use of esomeprazole,
the new proton pump inhibitor (18
reports). The most common reac-
tions were urticaria and skin rash.
In two patients, the medication was
suspected to be associated with he-
patitis. In both cases, involvement of
another drug was also suspected 
(azitromycin, rofecoxib).
Iopromide is a low-osmolar, io-
dine-containing contrast medium
used in angiography, urography and
contrast enhancement in comput-
erised tomography. A total of 23
adverse reactions were reported to
the National Agency for Medicines
in 2002, the majority of which in-
volved allergic reactions (urticaria,
anaphylaxis). Special care should be
exercised in the use of the prepara-
tion in patients with hypersensitivity
to  iodine. Hypersensitivity reactions
are more common in patients prone
to allergies. Prior to the contrast me-
dia administration,  antihistamines
and/or corticosteroids can be used
for prophylaxis of allergic reactions. 
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Despite its small size the drug pack-
age contains plenty of information
for the user of the drug. There is in-
formation found on the packaging
itself and in the leaflet inside the
package. 
The information on the outer
package ensures that the correct
drug is supplied. The Patient Infor-
mation Leaflet (PIL) in the package
contains information concerning the
indications, the dosage, and the ad-
verse effects. All these details should
be based on the approved Summary
Product Characteristics (SPC) of the
drug. The primary responsibility for
the correctness of the information
and for its being understood lies
with the marketing authorisation
holder and the manufacturer. The
authorities assess the factual con-
tents of the information at the pro-
cessing stage of the marketing au-
thorisation.
Summary of Product Characteristics 
The SPC is a drug description de-
signed on the basis of research re-
sults and aimed at medical pre-
scribers and other health care pro-
fessionals. The aim is to give ade-
quate and up-to-date information
about the drug and thereby ensure
successful treatment. The SPC ap-
proved in association with the mar-
keting authorisation approval
process is an essential part of the
marketing authorisation and should
form the basis of all the information
given concerning the drug and its
marketing. After approval the SPC
may not be changed without the
consent of the authorities.
Patient Information Leaflet 
The marketing authorisation holder
draws up a legible and comprehensi-
ble Patient Information Leaflet,
based on the SPC and intended for
the user of the drug. Naturally the
text of the SPC intended for drug
prescribers is not such as is appro-
priate for patients. The PIL follows
the normative headings given by the
authorities and an established order
of presentation. The PIL contains
headings taken from questions fre-
quently asked by patients, and the
replies are presented in clear lan-
guage. Typical questions are, for ex-
ample, What does the drug contain?,
What is the effect of the drug? etc.  
As an aid in the design of the
PIL, a legibility study can be used,
by which it is possible to assess the
clarity of the information given in
the PIL, the sequence of the details
presented, and the actual presenta-
tion.
A good PIL has a clear, simple and
short structure comprehensible to
the user. The user is generally only
interested in the type of information,
which will give a clear answer to the
question of what he or she should
do and what is to be expected. Clear
instructions for use and on how to
deal with emergencies are essential.
The text of the PIL should avoid un-
necessary general information,
which may submerge any message
essential for the use of the drug.
Positive instructions and active lan-
guage targeted directly at the patient
are preferred.
The presentation is of great im-
portance from the point of view of
readability and comprehensibility.
The text should be of sufficiently
large type and easily readable. Dif-
ferent colours and text sizes may be
used for distinguishing purposes.
Clear listings of adverse effects, for
example, improve the understanding
of the message. The following is a
list of some general observations as-
sociated with readability:
-  It is recommended that the headings
be emphasised with different colours
-  Numbering of the main headings will
help the reader to follow the text of
the PIL; this is especially important
when the PIL is double-sided or folded 
-  The main headings should be placed
on the left, not centered
-  The text size of the main headings
should be a minimum of 13 points
-  The less important information (the
marketing authorisation holder and
manufacturer, addresses) may be writ-
ten in smaller style
-  Bulletins should be used instead of
lists of texts. 
Test of readability of the PIL
The EU drug legislation requires
that the Patient Information Leaflets
should be clear and comprehensible.
The current guidelines also mention
a readability test, which is to be car-
ried out among the PIL users, and
which will allow the comprehensi-
bility and clarity of the PILs to be
studied. The Guideline on the read-
ability of the label and package
leaflet of medicinal product for hu-
man use was approved in 1998. The
guideline recommends the use of a
readability test developed in Aus-
Summary 
Jussi Holmalahti
D. Sc. (Pharm.) 
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tralia to be used in the assessment of
clarity and comprehensibility of
PILs. If others methods than the EU
model are used in the design of the
PIL, the testing of readability is en-
tirely the responsibility of the mar-
keting authorisation holder. 
For several years there has been
particular attention paid to associa-
tion of the readability testing with
the centralised procedure of market-
ing authorisation approval process-
es. The PILs of a number of drug
products have been put through the
readability test in accordance with
the EU guideline. These tests have
permitted better understanding of
the problems associated with PILs.
The readability is tested with
questions, some of which directly
concern the factual content of the
PIL. A typical question could be, for
example: Imagine that you are aller-
gic to penicillin, could you in that
case use penicillin? Some of the
questions are aimed at testing the
general structure of the PIL (e.g. the
ease or difficulty of finding required
information) and could typically be:
What are the disadvantages of the
Patient Information Leaflet, and
how could it be improved?. The
time allowed for the test is naturally
limited. The readability test can be
carried out in two stages, which will
provide an opportunity to find out
whether the improvements made on
the PIL have had any effect on the
readability.
There are complexities involved
in the readability test. The test
methods are not yet quite estab-
lished, and the testing of the reliabil-
ity of the various methods is inade-
quate. The question is: Are we test-
ing the readability of the Patient In-
formation Leaflets or the compre-
hensibility of the list of questions?
In accordance with the EU guide-
line, the various languages are divid-
ed into three groups, and one lan-
guage of each group is required for
the testing of readability:
A French, Italian, Portuguese and Spanish
B Dutch, English, German
C Danish, Finnish, Greek and Swedish
Some of the languages, especially
those in group C, are not related to
each other, which makes it doubtful
whether any conclusions can be
drawn from the results. A review of
the analysed tests shows that there
have seldom been any important dif-
ferences between the results from
different countries, which is why the
testing of various language versions
should be expanded.
Conclusion
The content and quality of informa-
tion supplied with the drug products
are one of the more specifically de-
fined areas associated with the prod-
ucts for sale. The size of drug pack-
ages is rather small; inserting ade-
quate labelling which would satisfy
everybody on the outer package is
consequently impossible. Including
all information essential for the
choice of OTC drugs in the Patient
Information Leaflet is, of course,
difficult. In the selection of services
the pharmacies offer they should
therefore focus on whether it is pos-
sible for the patients to familiarise
themselves with the information
leaflet. The PILs in Finnish and in
Swedish for drugs marketed in Fin-
land can be obtained from the web-
site of the National Agency for
Medicines under the heading Lääke-
informaatio (www.nam.fi).
Patient Information Leaflets are
sources of information which com-
plement the package labelling. The
readability testing of PILs is an im-
portant stage in the process of refin-
ing the texts contained in the SPCs
to make them comprehensible to the
users. Readability testing of PILs is
not legally required by the authori-
ties, but the tests may improve the
PILs. The responsibility of PILs lies
distinctly with the marketing autho-
risation holder, whereas the correct-
ness of the factual contents is
checked by the authorities. From the
patient’s viewpoint, the implementa-
tion of readability testing could be a
step towards improved drug infor-
mation.
Information given in the drug
packaging
• The name of the drug product consists
of a trade name, strength and dosage
form of drug. The name should be un-
ambiguous, in order to enable it to be
distinguished from other drug prod-
ucts and from items of the same
group of products.
• The package should also contain the
name of the medicinal substance,
and, in some cases, the complete de-
claration of the drug. All excipients
used are detailed in the PIL. The quan-
tities of excipients are only given in
special cases. The colorants used in
the drug products are approved for
use in food products. The codes of
colorants are given on the outer pack-
aging.
• Instructions for use, indications and
usual dosage intended for the patient
are only given on the outer packaging
of OTC drugs. The usual dosage and
indications of prescription drugs are
given in the PILs. The PIL will also in-
clude a reminder of the fact that the
doctor may have prescribed the drug
with different dosages or different
therapeutic indications.
• The package will always include in-
structions for storage of the drug, ac-
cording to which the quality of the
product will remain unimpaired until
the expiry date marked on the pack-
age. The outer and inner packaging
will also include a batch number,
which will restrict any possible com-
plication that may arise from a partic-
ular production batch.
• The package will also include details
of the name and address of the mar-
keting authorisation holder, which will
help the patient to obtain further in-
formation about the drug.
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Antipsychotics are mainly used for
the treatment of symptoms of schiz-
ophrenia, but also of delusional psy-
chosis or personality disorder, severe
depression or other affective syn-
drome, or for the prevention of re-
currence of symptoms. Antipsy-
chotics are also used for the treat-
ment of, for example, psychic disor-
ders of the elderly and mentally re-
tarded, e.g. anxiety, delusion and
confusion, and for the alleviation of
psychotic symptoms associated with
the use of intoxicants (1).
Antipsychotics can be divided in-
to two main groups: conventional
and second-generation antipsy-
chotics (Table 1). The division is
based on the various mechanisms of
action of the drugs. The main an-
tipsychotic effect of the conventional
antipsychotics is based on the
dopamine-2-receptor blockade, espe-
cially in the mesolimbic and meso-
cortical area of the brain. The more
primary blockade by second-genera-
tion antipsychotics is targeted at the
dopamine receptors of the limbic
area and the receptors 5-HT2A and
5-HT2C among the serotonin-recep-
tors (2).
Conventional antipsychotics di-
minish the positive symptoms of
psychosis in particular, including
hallucinations, delusions and psy-
chomotor anxiety. On the other
hand second-generation antipsy-
chotics may alleviate especially the
negative symptoms of psychosis, e.g.
emotional withdrawal. They cause
fewer adverse reactions than con-
ventional antipsychotics and treat-
ment compliance can therefore be
expected to be better. The use of sec-
ond-generation antipsychotics is
nevertheless restricted by their high
price (3). 
Total consumption
The following is a review of the con-
sumption of antipsychotics as de-
tailed in the wholesalers’ drug sales
register maintained by the National
Agency for Medicines in Finland.
The antipsychotics referred to here
are drugs of the ATC Code N05A,
except for lithium.
The total consumption of an-
tipsychotics has not changed signifi-
cantly during 1995–2001. The
choice of drug has changed, howev-
er, over the years. The consumption
of conventional antipsychotics has
diminished and that of second-gen-
eration drugs increased (Fig. 1). In
The use of antipsychotics and the national social
insurance reimbursements in Finland 1995–2001
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1995, the consumption of second-
generation antipsychotics came to
10.3% and that of the conventional
variety to 89.7% of the total con-
sumption of antipsychotics (4). In
2001, the corresponding figures
were 38.8% and 61.2% (4). The
consumption of conventional an-
tipsychotics still remains above half
of the total consumption. Second-
generation antipsychotics can never-
theless be considered primary drugs
for patients who suffer from schizo-
phrenic psychosis for the first time,
or patients who suffer from adverse
reactions from conventional antipsy-
chotics and whose response to treat-
ment with these is poor (1).
Phenothiazines were the most
used antipsychotics in 1995, where-
as in 2001, those most used were
the second-generation antipsy-
chotics, diazepines and oxazepines.
Of these, the most used were olan-
zapine (2.22 DDD/1,000 inh/day),
clozapine (1.59 DDD/1,000 inh/day)
and risperidone (1.54 DDD/1,000
inh/day). The most commonly used
conventional antipsychotics in 2001
were perphenazine (1.29 DDD/1,000
inh/day), haloperidol (1.24 DDD/1,000
inh/day) and zuclopenthixol (1.21
DDD/1,000 inh/day) (4). 
Out-patient use of antipsychotics
is increasing. In 1995, the propor-
tion consumed in out-patient care
was 75% and in 2001 it had already
reached 80%. The cause for the de-
velopment is the reduction of beds
in institutional care and the transfer
of patients to out-patient care (5).
Olanzapine and clozapine were
the antipsychotics most used in out-
patient care in 2001 (Fig. 2). In in-
patient use up until 1999, clozapine
was the mostly used antipsychotic,
followed by olanzapine. Out-patient
use of olanzapine grew by 31% and
in-patient use by 14% in 2001 com-
pared with the previous year. The
rapid increase in out-patient con-
sumption is likely to have been
caused by the fact that olanzapine
fell into the category of special re-
fund in the national health insurance
scheme in the year 2000.
Table 1.  Antipsychotics divided
into groups with their ATC Codes.
Medicinal substances on the mar-
ket in Finland in 1995–2001 have
been included.  
CONVENTIONAL ANTIPSYCHOTICS
N05AA  Phenothiazines with
aliphatic side chain
N05AA01   chlorpromazine
N05AA02   levomepromazine
N05AA03   promazine
N05AB   Phenothiazines with
piperazine structure 
N05AB01    dixyrazine
N05AB02    fluphenazine
N05AB03    perphenazine
N05AB04    prochlorperazine 
N05AB08    thioproperazine* (1999)
N05AC   Phenothiazines with
piperidine structure 
N05AC01   periciazine  
N05AC02   thioridazine 
N05AC04   pipothiazine* (1997)
N05AD   Butyrophenone deriva-
t ives 
N05AD01   haloperidol
N05AD03   melperone
N05AE   Indole derivatives 
N05AE02    molindone* (1998)
N05AE03    sertindole
N05AF   Thioxanthene derivatives
N05AF01    flupentixol 
N05AF03    chlorprothixene
N05AF04    thiothixene* (1995)
N05AF05    zuclopenthixol
N05AG   Diphenyl butylpiperidine
derivatives 
N05AG02    pimozide* (1995)
SECOND-GENERATION ANTI-
PSYCHOTICS
N05AH   Diazepines and oxazep-
ines
N05AH02   clozapine
N05AH03   olanzapine 
N05AH04   quetiapine
N05AL   Benzamides
N05AL01    sulpiride
N051AX  Other antipsychotics 
N05AX08    risperidone
Source: Finnish Statistics on Medicines
1995–2001
* Marketing authorisation cancelled in
the year indicated in brackets
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Table 2.  National  health insurance refunds received for  antipsychotics during 1995 and 2001.  Includes only
drugs for  which over  1 ,000 patients/year  have received refunds.  Source: Social Insurance Institution, prescription regis-
ter
1995 2001 
Proportion (%) Proportion (%) Change (%) 
No. of of special refund No. of of special refund  in the No. of
recipients recipients of all recipients recipients  of all recipients of 
of refunds refund recipients of refunds refund recipients refunds
CONVENTIONAL ANTIPSYCHOTICS 109 127 44 90 562 46 -17
Phenothiazines with al iphatic  
s ide chain 28 275 53 23 171 56 -18
chlorpromazine 7 519 80 4 906 84 -35
levomepromazine 21 899 46 18 946 50 -13
Phenothiazines with piperazine 
structure 41 051 38 31 817 39 -22
dixyrazine 3 589 14 3 298 12 -8
fluphenazine 3 976 30 2 188 31 -45
perphenazine 21 495 64 17 798 63 -17
prochlorperazine 12 389 3 8 830 3 -29
Phenothiazines with piperidine
structure 22 592 69 14 686 74 -35
periciazine 3 876 37 2 418 44 -38
thioridazine 18 722 76 12 410 80 -34
Butyrophenone derivatives 22 357 37 19 488 34 -13
haloperidol 13 617 48 11 420 44 -16
melperone 9 547 22 8 533 19 -11
Thioxanthene derivat ives 21 892 64 18 107 68 -17
flupentixol 6 159 34 4 012 37 -35
chlorprothixene 10 841 72 9 748 71 -10
zuclopenthixol 6 062 86 5 180 91 -15
SECOND-GENERATION ANTI-
PSYCHOTICS 11 009 58 38 606 59 +251
Diazepines and oxazepines 2 367 97 16 138 71 +582
clozapine 2 367 97 5 501 97 +132
olanzapine - - 10 163 62 -
quetiapine - - 1 163 - -
Benzamides 7 075 39 3 874 40 -45
sulpiride 7 075 39 3 874 40 -45
Other  ant ipsychotics 1 815 83 20 731 53 +1 042
risperidone 1 815 83 20 731 53 +1 042
Al l 115 322 44 116 137 48 +1
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Reimbursements for anti-
psychotics 
A review of out-patient consump-
tion of antipsychotics can also be
obtained from the drug reimburse-
ment record of the national social
insurance scheme. Antipsychotics
may be included in the special re-
fund category for patients with se-
vere psychosis or other severe men-
tal disorders, and also for the men-
tally retarded patients with anxiety
disorders. Patients using the drugs
with other disorders are entitled to a
basic refund. The number of pa-
tients entitled to a special refund is
slightly lower than that of patients
receiving basic refunds. In 2001, an
average of 48% of patients on an-
tipsychotics received special refunds
for at least one of the antipsychotics
they used (Table 2). The quantity of
drugs used by those entitled to spe-
cial refunds (calculated in DDDs) is
nevertheless larger than that used by
those entitled to basic refunds only,
the likely cause for this being that
those entitled to special refunds use
their drugs in larger quantities and
more continuously, or for longer pe-
riods, than other users of antipsy-
chotics (6).
The change in the choice of
drugs seen in the consumption sta-
tistics is also reflected in the drug re-
imbursement statistics. In 1995, a
total of 109,000 persons were enti-
tled to refunds on conventional an-
tipsychotics, whereas in 2001 the
figure had dropped to 90,000. The
drop in the numbers of patients re-
ceiving refunds is shown most ex-
plicitly in the group of patients us-
ing phenothiazines. The number of
patients receiving second-generation
antipsychotics increased from
11,000 to 38,600 during the same
period. In 2001, based on the num-
ber of users who had received re-
funds, it is clear that the refunds
were mostly given for risperidone:
refunds were received by nearly
21,000 persons. The most frequently
used conventional antipsychotics
were levomepromazine (refunds re-
ceived by 19,000 people) and per-
phenazine (refunds received by
18,000 people).
A review of the proportion of
patients having received special re-
funds also shows that some chan-
nelling has occurred in the prescrip-
tion of second-generation antipsy-
chotics. Since soon after their intro-
duction on to the market, clozapine
and risperidone have been pre-
scribed mainly for patients who
were entitled to a special refund for
their antipsychotic drugs. Risperi-
done has since also been prescribed
to other patients.
Costs
Even though the total consumption
of antipsychotics has hardly in-
creased, their costs have increased
rapidly during the past seven years.
The national health insurance statis-
tics show an increase from EUR 135
to EUR 364 in the average annual
costs per patient at the same time.
The increase in the costs is the result
of increased use of more expensive
second-generation antipsychotics,
but the transfer of psychotic patients
to out-patient care has also in-
creased the costs of drugs slightly.
The highest wholesale costs in 2001
resulted from the use of olanzapine
(EUR 16.2 million) and risperidone
(EUR 9.5 million) (4).
Conclusion
The use of conventional antipsy-
chotics has been replaced increasing-
ly by that of second-generation an-
tipsychotics in both the out- and in-
patient treatment of psychosis. The
increasing use of second-generation
antipsychotics in out-patient treat-
ment is partly the result of the supe-
rior tolerability of these drugs and
also partly due to their inclusion in
the special refund category in the
national health insurance scheme.
This development has multiplied the
costs of antipsychotics during
1995–2001.
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A defibrillator is a device used dur-
ing ambulance transports, first aid
and intensive care.  Its purpose is to
eliminate life-threatening cardiac ar-
rhythmia and to restore the heart’s
normal pumping activity by apply-
ing a powerful direct-current electric
shock to the patient’s chest. Defibril-
lation immediately following a car-
diac arrest results in a patient sur-
vival rate as high as 80%, and a
third of the patients survive even af-
ter ‘out-of-hospital’ defibrillation.
The general condition of the patient
and the duration of the cardiac ar-
rest prior to commencing the (basic)
resuscitation will affect the survival.
Conventional manual defibrilla-
tors have been in therapeutic use for
decades. The proportion of auto-
mated external defibrillators (AED)
among all devices in use has in-
creased significantly, especially dur-
ing the last decade. The patient’s
physiological functions are moni-
tored and analysed by the device
which can also, as necessary, advise
the user with display and voice
prompts on the method and timing
of the treatment. Defibrillators in-
tended for use by health care profes-
sionals are semi-automated, which
allows the user to make important
decisions pertaining to the treatment
himself/herself. Automated, compact
devices easy to use are also found on
the market; they are appropriate for
defibrillation carried out by non-
medical personnel also practised in
Finland.
The manufacturer and the user
are both responsible for the per-
formance of the device
Medical devices should be designed
and manufactured so as not to jeop-
ardise the health and safety of the
patient or the user when used in ac-
cordance with their purpose. The
manufacturer should therefore aim
at identifying all apparent hazards
associated with the properties, per-
formance and use of the device, and
minimising any consequential risks,
as early as at the stage of designing
and manufacturing. Risks associated
with use should be clearly stated in
the instructions for use and in the
labelling of the device.
As to the condition and opera-
tion of medical devices, it is the re-
sponsibility of the professional user
to ensure that they are maintained
at the level required by regulations
during the entire period of use.
Compliance with special conditions
relating to their storage, use, mainte-
nance and service is required, in-
cluding instructions for the carrying
out of these operations. It is impor-
tant that users receive adequate
training in the use of the devices and
have knowledge of any risks associ-
ated with their use. Experience in
using them should be maintained at
all times and further training
arranged as required. Important la-
belling information and details per-
taining to the safety of the device,
including appropriate instructions
for use, should receive special atten-
tion at the time of purchase and
should be made available on re-
quest. According to Finnish legisla-
tion, information pertaining to the
safe use of devices should be provid-
ed in both Finnish and Swedish.
New defibrillators speak the 
correct language
In the autumn of 2002, the National
Agency for Medicines decided to
carry out a review of the new mod-
els of defibrillators marketed in Fin-
land at present. Compliance with
regulations relative to their instruc-
tions for use, display and voice mes-
sages, and the frequency of training
arranged by the distributors of the
manufacturers of the device, were
reviewed. A questionnaire was sent
out to 11 Finnish companies, which
were assumed to market defibrilla-
tors at the time. 
Six Finnish companies reported
as marketers of defibrillators. The
replies consisted of reports on 13
models of devices on the market at
present, manufactured by six differ-
ent manufacturers. Six of the models
were claimed to be appropriate for
use also by non-professionals in the
automated external mode (AED).
Instructions for use and labelling,
and information essential for the
safety of use, were supplied in
Finnish for 12 and in Swedish for
nine devices. Ten devices had display
and voice prompts  in Finnish, and 9
devices in Swedish. The instructions
for use of one device were only pro-
vided in English at the time of the
questionnaire, but its Finnish ver-
sion was being prepared.
All companies reported that they
offered training in the use of the de-
vice at the time of supply and fur-
ther training on request by the
client. Only one distributor claimed
to arrange regular training for the
company’s clients.
Only very few adverse incidents 
During 1995–2002 the National
Agency for Medicines received a to-
tal of 32 reports of adverse incidents
relative to defibrillators: Seventeen
reports (from 13 users) were on
Finnish incidents, five reports were
submitted by manufacturers them-
selves on the corrective measures
they had taken on their devices, and
10 were submitted by the authorities
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reporting on measures taken by
manufacturers. Seven of these re-
ports on corrective measures did not
concern Finland.
The reason for corrective mea-
sures in general was the increased
frequency of defects detected in the
electrical or mechanical components
of certain models or batches of
products, or problems that were de-
tected in the operation of the soft-
ware of the device.
Four of the Finnish incidents in-
volved a fatal accident, six involved
a serious incident, five involved a
near-incident and two were in rela-
tion to ambiguities associated with
the instructions for use or properties
of monitoring. In relation to the
large number of defibrillators in use
and the critical use of the devices,
the frequency of serious incidents is
unexpectedly low; only 10 cases
during the last eight years.
The number of serious incidents
is very likely to be higher than the
number reported to the National
Agency for Medicines. Such an inci-
dent should always be reported
when there is reason to believe that
the performance or other properties
of the device (including usability)
have resulted in the development of
an adverse event or a fatality, or
when it did not have serious conse-
quences at the time, but could have
a serious consequence if recurred.
The user should report any haz-
ardous incidents to both the distrib-
utor or manufacturer and the au-
thority. The reporting is essential be-
cause sharing the background infor-
mation on hazardous incidents is the
only way of helping others to avoid
similar incidents and take appropri-
ate measures should one occur. The
intention is not to blame anybody,
but to learn.
Contributory reasons for an ad-
verse incident
A serious incident may have been
caused by a certain property of the
device which, despite the manufac-
turer’s necessary risk analysis, is not
detected until the device is being
properly used – perhaps not until
years after it has been taken into
use. 
A case was reported last year in
which, as part of their scheduled
maintenance operations, the techni-
cal service personnel in a hospital
detected that all the defibrillators
purchased in 1998 had faulty power
supply units. Fortunately, nothing
serious happened as the faults were
detected before the devices were
needed in an actual resuscitation.
Faulty power supply units are well-
known complications in defibrilla-
tors and they have occurred sporadi-
cally or, as in this case, they may
have been associated with a certain
production batch. Both of the two
fatalities that occurred in 1996 took
place in ambulances, when the elec-
trodes were damaged due to difficul-
ty in removing the protective plastic
covers, and defibrillation was conse-
quently unsuccessful. This particular
model of electrode was subsequently
withdrawn from the market and the
durability of the new electrodes and
the feasibility of the covers were im-
proved. The importance of the cor-
rect handling of electrodes was also
emphasised.
It is very important that the per-
formance and operation of defibril-
lators as well as other medical de-
vices be checked at health care units
as part of their routine procedures.
The personnel should be trained to
detect malfunctions of the devices or
signs or symptoms indicative of such
malfunction.
Despite regular checks on the op-
eration, normal wear and tear of
medical devices during use or an in-
dividual defect may result in an
unanticipated adverse event. In an
incident which occurred in 2001, the
cable between the defibrillator and
the electrode was broken, preventing
instant treatment of the patient. In
another incident occurring in the
same year, the ECG cable of the de-
fibrillator was faulty, causing ven-
tricular fibrillation in the patient as
a result of the twisting cable and the
unsynchronised defibrillator shock
received from the device. In a third
case, the contact between the cable
and the electrode of a certain type
was poor, resulting in a delay in the
treatment. In all these cases, howev-
er, the patients were successfully re-
suscitated. A spare device and spare
supplies important for the treatment
(e.g. electrodes, cables, and fully
charged batteries) should be readily
available in order to manage unex-
pected situations and avoid fatal
consequences.
Inadequate instructions for use,
or inadequate skills of the user may
also contribute to the development
of a seriously hazardous incident.
Use error can be considered to be
the cause for only one of the Finnish
cases. In this case, the alarm func-
tion of the defibrillator used in a
monitoring situation had been
switched off; ventricular fibrillation
in the patient was fortunately detect-
ed in time and treated successfully.
A fatal incident occurred in an am-
bulance in 1997 due to a battery be-
ing inadequately charged. As a result
of the event the user changed the
standard operating  procedures of
charging the batteries. The above
case with the poor connection be-
tween cable and electrode also
prompted the user to change the
guidelines for the use of electrodes.
All the three serious incidents
last year were associated with faulty
operation, which was detected as the
device was being used, and were not
possible to repeat in test situations
following the incident; consequently,
the actual causes remained unclear.
The underlying causes for these in-
explicable faults in operation may
well be associated with the increased
complexity of the devices. The oper-
ation of the more recent models of
defibrillators is, to an increasing de-
gree, based on the computerised
identification of physiological sig-
nals and associated conclusions. 
Serious incidents are very infre-
quent at present. The near future
will show whether the proneness to
faulty operation and to defects will
increase with the increasing variety
of operations and automation. The
professional skills of the user and
his/her ability to use the device even
in unexpected situations, and early
detection of any associated compli-
cations, are nevertheless important
for successful treatment. Mainte-
nance of these skills should be con-
tinually emphasised.
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